Movement Disorders Clinical Trials

Find Movement Disorders Clinical Trials Near You

The Social-HD Study: A Cross-Sectional Observational Study of Social Cognition in Early Huntington Disease

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease. Huntington disease affects motor function, psychological well-being and cognitive functions (thinking abilities such as paying attention, remembering and solving problems). It is also believed to affect important social functions, including the ability to understand others' intentions and emotions (social cognition). The test of interest in this study is called The Double Movie for the Assessment of Social Cognition-Multiple Choice (DMASC-MC) and will be compared to two other similar and well-known tests. The main question which the study aims to answer is: • Is DMASC-MC a useful tool for detecting problems with social functioning in adult persons with early Huntington disease? In the study, participants will meet with a medical doctor and a psychologist for assessment of different symptoms related to Huntington disease, including social functioning. Better methods for identifying problems with social functioning could help persons with Huntington disease and their families in mainly two ways. Firstly, it could increase their understanding of how the disease has affected them. Secondly, a better understanding of these problems could lead to better recommendations and interventions from medical teams, which would also benefit persons with Huntington disease and families.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• Clinical diagnosis of HD

• CAG repeat: 40 and more

⁃ 1\. No heritage of HD or negative pre-symptomatic HD gene test

Locations
Other Locations
Sweden
Skane University Hospital, Region Skane
RECRUITING
Lund
Contact Information
Primary
Asa Petersen, MD, PhD
asa.petersen@med.lu.se
+46462221686
Backup
Isak Halling, MSc
isak.halling@skane.se
+4646178188
Time Frame
Start Date: 2025-12-01
Estimated Completion Date: 2027-09-01
Participants
Target number of participants: 40
Treatments
Huntington disease
Participants with early Huntington disease
Controls
Participants with no heritage of HD or negative pre-symptomatic HD gene test
Sponsors
Leads: Region Skane

This content was sourced from clinicaltrials.gov